Carl Zeiss Meditec clearly on growth course
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG / Carl Zeiss Meditec clearly on growth course processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Revenue in the first nine months of financial year 2009/2010 increases to
EUR 490.8 million - positive outlook for the year confirmed
JENA - 12 August 2010.
With a 20 percent increase in revenue in the third quarter compared with the
same quarter of the previous year, Carl Zeiss Meditec generated a very solid
result and is thus clearly on a growth course. The Company grew by a total of
3 percent in the first nine months of financial year 2009/2010, to EUR 490.8
million (previous year: EUR 478.5 million) and increased its gross margin by
1.7 percentage points year-on-year, to 52.1 percent. Earnings before interest
and tax rose by 11.8 percent to EUR 60.0 million; the EBIT margin increased to
12.2 percent (previous year: 11.2 percent).
"We did all our homework during the times of global economic crisis - for us,
this also included continuing to strategically invest in our innovative
strength. This policy is now paying off - which is clear not only from our
figures today," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec
AG.
Regionally, the Company is benefiting from more stable markets overall. With
almost 10 percent, the "Asia/Pacific" region continues to be the growth driver.
The "Americas" region is being stimulated by a growing demand in the USA - the
Company's largest market. "Europe, Middle East and Africa" is the only region
where perceptible uncertainties persist; however, these uncertainties were
significantly overcompensated by the other two regions.
On the level of the strategic business units, the "Surgical Ophthalmology" SBU
once again proved its high future potential, growing by 6 percent compared with
the first nine months of 2008/2009. The "Microsurgery" SBU also grew by around
6 percent, while the "Ophthalmic Systems" SBU showed stable development.
"Given our successful development, particularly in the third quarter, we
anticipate total revenue for financial year 2009/2010 of between EUR 660 million
and EUR 670 million. We are aiming to increase our EBIT margin by around
40 base points compared with the previous year," says Dr. Ludwin Monz. "We
already laid the foundations for profitable growth in 2008 with our corporate
programme, RACE 2010. This has clearly paid off. We are more than confident that
we will be able to stay on this successful track and accelerate our growth with
the successor programme due to start in the coming financial year."
Revenue by strategic business unit
+----------------------+------------------+------------------+-----------------+
|Figures in |9 Months 2008/2009|9 Months 2009/2010|Change from |
|EUR '000 | | |previous year |
+----------------------+------------------+------------------+-----------------+
|Ophthalmic Systems |232,238 |231,660 |-0.2% |
| | | | |
+----------------------+------------------+------------------+-----------------+
|Surgical Ophthalmology|61,566 |65,039 |+5.6% |
| | | | |
+----------------------+------------------+------------------+-----------------+
|Microsurgery |184,730 |194,132 |+5.1% |
+----------------------+------------------+------------------+-----------------+
Revenue by region
+------------+------------------+------------------+-------------------------+
|Figures in |9 Months 2008/2009|9 Months 2009/2010|Change from previous year|
|EUR '000 | | | |
+------------+------------------+------------------+-------------------------+
|EMEA |184,590 |181,296 |-1.8% |
+------------+------------------+------------------+-------------------------+
|Americas |165,733 |168,964 |+1.9%*) |
+------------+------------------+------------------+-------------------------+
|Asia/Pacific|128,211 |140,571 |+9.6% |
+------------+------------------+------------------+-------------------------+
*) currency-adjusted: +5.4%
Contact:
Eva Sesselmann Patrick Kofler
Director Group Communications Director Investor Relations
Carl Zeiss Meditec AG Carl Zeiss Meditec AG
Göschwitzer Straße 51-52 Göschwitzer Straße 51-52
07745 Jena 07745 Jena
Phone: +49 3641 220-331 Phone: +49 3641 220-106
Fax: +49 3641 220-332 Fax: +49 3641 220-117
E-mail:press(at)meditec.zeiss.com E-mail:investors(at)meditec.zeiss.com
[HUG#1437392]
--- End of Message ---
Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany
WKN: 531370;ISIN: DE0005313704;Index:TecDAX,Prime All Share,TECH All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 12.08.2010 - 07:01 Uhr
Sprache: Deutsch
News-ID 39466
Anzahl Zeichen: 0
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec clearly on growth course"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
